R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
The move strengthens GBL’s clinical-stage presence in the United States
India plays a critical role in Bristol Myers Squibb’s global strategy
Clinical trial enrollment has long been a bottleneck in drug development
Subscribe To Our Newsletter & Stay Updated
